What is Profound Medical's operating income?

Profound Medical's total operating income in 2025 was -$41.25 million, based on the following breakdown: Total Gross Profit: $11.39 million Total Operating Expenses: $52.65 million

Profound Medical (PROF) Financials

$7.26 +0.41 (+5.99%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$7.27 +0.01 (+0.14%)

As of 07/24/2026 07:34 PM Eastern

Compare

Annual Income Statements for Profound Medical

This table shows Profound Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-15	-15	-22	-31	-29	-28	-28	-43
Consolidated Net Income / (Loss)	-15	-15	-22	-31	-29	-28	-28	-43
Net Income / (Loss) Continuing Operations	-15	-15	-22	-31	-29	-28	-28	-43
Total Pre-Tax Income	-15	-15	-22	-31	-28	-28	-28	-42
Total Operating Income	-15	-15	-19	-30	-32	-29	-33	-41
Total Gross Profit	0.60	2.39	3.47	2.95	3.02	4.31	7.04	11
Total Revenue	1.91	4.17	7.30	6.87	6.68	7.20	11	16
Operating Revenue	1.91	4.17	7.30	6.87	6.68	7.20	11	16
Total Cost of Revenue	1.30	1.78	3.83	3.92	3.66	2.89	3.64	4.71
Operating Cost of Revenue	1.30	1.78	3.83	3.92	3.66	2.89	3.64	4.71
Total Operating Expenses	15	17	22	33	35	33	40	53
Selling, General & Admin Expense	7.88	7.90	12	18	18	19	23	32
Research & Development Expense	7.52	9.40	9.91	15	15	14	17	21
Total Other Income / (Expense), net	-0.25	-0.17	-2.71	-0.30	3.74	0.20	5.24	-1.06
Interest & Investment Income	-	-	-	-	-	0.78	1.44	1.07
Other Income / (Expense), net	-0.25	-0.17	-2.71	-0.30	3.74	-0.58	3.81	-2.13
Income Tax Expense	0.17	0.15	0.05	0.11	0.29	-0.13	-0.00	0.25
Basic Earnings per Share	$1.52	$1.37	$1.25	$1.50	$1.38	$1.34	$1.12	$1.41
Weighted Average Basic Shares Outstanding	-	11.85M	20.21M	20.78M	20.88M	21.18M	24.77M	30.23M
Diluted Earnings per Share	$1.52	$1.37	$1.25	$1.50	$1.38	$1.34	$1.12	$1.41
Weighted Average Diluted Shares Outstanding	-	11.85M	20.21M	20.78M	20.88M	21.18M	24.77M	30.23M
Weighted Average Basic & Diluted Shares Outstanding	-	11.85M	20.21M	20.78M	20.88M	21.37M	30.04M	36.29M

This table shows Profound Medical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-6.59	-6.92	-9.37	-4.95	-11	-16	-7.98	-8.17	-7.05
Consolidated Net Income / (Loss)	-6.59	-6.92	-9.37	-4.95	-11	-16	-7.98	-8.17	-7.05
Net Income / (Loss) Continuing Operations	-6.59	-6.92	-9.37	-4.95	-11	-16	-7.98	-8.17	-7.05
Total Pre-Tax Income	-6.55	-6.90	-9.19	-5.19	-11	-16	-7.86	-8.15	-7.03
Total Operating Income	-7.88	-7.84	-9.00	-8.35	-11	-14	-8.91	-7.37	-8.02
Total Gross Profit	0.87	1.42	1.79	2.96	1.85	1.62	3.93	3.99	3.83
Total Revenue	1.44	2.23	2.83	4.18	2.62	2.21	5.29	5.98	5.34
Operating Revenue	1.44	2.23	2.83	4.18	2.62	2.21	5.29	5.98	5.34
Total Cost of Revenue	0.57	0.81	1.04	1.21	0.77	0.59	1.36	1.99	1.51
Operating Cost of Revenue	0.57	0.81	1.04	1.21	0.77	0.59	1.36	1.99	1.51
Total Operating Expenses	8.74	9.26	11	11	13	15	13	11	12
Selling, General & Admin Expense	4.80	5.06	6.62	6.66	8.21	9.33	7.43	7.09	6.59
Research & Development Expense	3.95	4.21	4.17	4.65	4.81	6.10	5.42	4.27	5.26
Total Other Income / (Expense), net	1.33	0.94	-0.19	3.16	0.48	-1.83	1.06	-0.78	0.99
Interest & Investment Income	0.46	0.42	0.22	0.33	0.45	0.34	0.12	0.16	0.38
Other Income / (Expense), net	0.87	0.52	-0.41	2.83	0.04	-2.17	0.94	-0.94	0.62
Income Tax Expense	0.04	0.02	0.18	-0.24	0.04	0.06	0.12	0.03	0.03
Basic Earnings per Share	$0.27	$0.28	$0.38	$0.19	$0.36	$0.52	$0.26	$0.27	$0.19
Weighted Average Basic Shares Outstanding	24.30M	24.44M	24.53M	24.77M	30.04M	30.05M	30.10M	30.23M	36.30M
Diluted Earnings per Share	$0.27	$0.28	$0.38	$0.19	$0.36	$0.52	$0.26	$0.27	$0.19
Weighted Average Diluted Shares Outstanding	24.30M	24.44M	24.53M	24.77M	30.04M	30.05M	30.10M	30.23M	36.30M
Weighted Average Basic & Diluted Shares Outstanding	-	-	-	30.04M	30.05M	30.05M	30.19M	36.29M	36.34M

This table details how cash moves in and out of Profound Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-8.64	67	-17	-19	-21	31	2.69
Net Cash From Operating Activities	-15	-21	-22	-26	-23	-23	-38
Net Cash From Continuing Operating Activities	-15	-21	-23	-26	-23	-24	-38
Net Income / (Loss) Continuing Operations	-15	-22	-31	-29	-28	-28	-43
Consolidated Net Income / (Loss)	-15	-22	-31	-29	-28	-28	-43
Depreciation Expense	0.66	0.66	0.85	0.90	0.73	0.71	0.37
Amortization Expense	0.86	0.88	1.03	0.70	0.20	0.23	0.19
Non-Cash Adjustments To Reconcile Net Income	0.48	4.52	7.09	5.13	3.94	2.58	5.98
Changes in Operating Assets and Liabilities, net	-1.37	-5.81	-1.05	-3.91	0.84	0.56	-2.18
Net Cash From Investing Activities	-0.19	-0.35	-0.59	0.00	0.00	0.00	-0.24
Net Cash From Continuing Investing Activities	-0.19	-0.35	-0.59	0.00	0.00	0.00	-0.24
Purchase of Property, Plant & Equipment	-0.19	-0.35	-0.59	-	-	0.00	-0.18
Acquisitions	-	-	-	-	-	0.00	-0.07
Net Cash From Financing Activities	6.60	87	5.95	7.03	1.76	55	41
Net Cash From Continuing Financing Activities	8.38	87	0.11	7.08	1.76	57	41
Repayment of Debt	-0.24	-0.29	-0.39	-0.46	-0.91	-4.90	-1.31
Issuance of Common Equity	8.71	86	0.00	-	0.00	62	42
Other Financing Activities, net	-0.09	1.61	0.50	0.26	2.67	0.05	0.01

This table details how cash moves in and out of Profound Medical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	16	-6.82	-7.42	30	-8.57	-14	-9.61	35	-8.58
Net Cash From Operating Activities	-4.53	-6.22	-6.83	-5.88	-8.28	-14	-9.61	-6.57	-8.58
Net Cash From Continuing Operating Activities	-4.53	-6.22	-6.83	-6.17	-8.28	-14	-9.61	-6.57	-8.58
Net Income / (Loss) Continuing Operations	-6.59	-6.92	-9.37	-4.95	-11	-16	-7.98	-8.18	-7.05
Consolidated Net Income / (Loss)	-6.59	-6.92	-9.37	-4.95	-11	-16	-7.98	-8.18	-7.05
Depreciation Expense	0.20	0.18	0.16	0.16	0.12	0.10	0.09	0.06	0.09
Amortization Expense	0.05	0.05	0.05	0.08	0.05	0.04	0.05	0.05	0.01
Non-Cash Adjustments To Reconcile Net Income	1.39	1.22	1.02	-1.05	1.62	1.89	1.78	0.68	1.21
Changes in Operating Assets and Liabilities, net	0.41	-0.75	1.31	-0.41	0.66	-0.08	-3.57	0.82	-2.84
Net Cash From Investing Activities	0.00	-	-	-	0.00	-	-	-0.24	0.00
Net Cash From Continuing Investing Activities	0.00	-	-	-	0.00	-	-	-0.24	0.00
Net Cash From Financing Activities	20	-0.60	-0.59	35	-0.29	-	-	41	0.00
Net Cash From Continuing Financing Activities	20	-0.60	-0.59	38	-0.29	-	-	41	0.00
Repayment of Debt	-2.48	-0.60	-0.59	-1.22	-0.29	-	-	-1.02	0.00
Cash Interest Paid	-	-	-	-	0.06	-	-	-	0.08
Cash Income Taxes Paid	0.01	0.16	0.04	-	0.01	0.05	0.04	-	0.03

This table presents Profound Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	1/1/2019	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	34	30	105	87	64	44	70	77
Total Current Assets	28	7.82	98	77	16	42	69	76
Cash & Equivalents	22	-	84	67	-	26	55	60
Accounts Receivable	1.97	3.13	7.43	1.41	6.34	7.29	7.05	7.20
Inventories, net	2.66	3.67	5.33	7.41	7.94	6.99	5.80	8.24
Prepaid Expenses	-	1.03	-	-	1.22	1.41	1.31	0.93
Plant, Property, & Equipment, net	0.89	-0.10	0.86	0.79	-0.06	0.91	0.43	0.70
Total Noncurrent Assets	5.44	22	6.00	8.86	49	1.15	0.74	0.69
Noncurrent Note & Lease Receivables	-	-	-	-	-	-	0.00	0.30
Intangible Assets	2.94	2.41	1.90	1.44	0.68	0.49	0.26	0.14
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	-	0.00	0.09	0.07
Other Noncurrent Operating Assets	0.00	17	1.42	4.74	48	0.66	0.40	0.18
Total Liabilities & Shareholders' Equity	34	30	105	87	64	44	70	77
Total Liabilities	15	16	7.25	6.16	12	13	9.81	11
Total Current Liabilities	5.78	3.04	4.81	4.16	2.33	6.37	6.57	6.08
Short-Term Debt	0.98	-	-	0.00	-	2.10	1.74	0.00
Accounts Payable	-	3.03	-	-	2.03	0.87	1.32	1.56
Accrued Expenses	-	-	-	-	-	2.42	2.84	3.82
Current Deferred Revenue	0.23	-	0.36	0.48	-	0.72	0.42	0.45
Current Deferred & Payable Income Tax Liabilities	-	0.01	-	-	0.30	-	0.00	0.04
Other Current Liabilities	1.48	-	1.06	0.50	-	0.26	0.26	0.21
Total Noncurrent Liabilities	8.10	27	2.44	2.00	62	6.36	3.25	4.97
Long-Term Debt	7.78	9.14	-	0.00	7.17	5.00	2.92	4.50
Noncurrent Deferred Revenue	0.28	1.14	1.08	0.88	1.24	0.73	0.05	0.39
Other Noncurrent Operating Liabilities	0.04	16	1.36	1.13	54	0.58	0.27	0.08
Total Equity & Noncontrolling Interests	20	0.00	97	81	0.00	31	60	66
Total Preferred & Common Equity	20	0.00	97	81	0.00	31	60	66
Total Common Equity	20	0.00	97	81	0.00	31	60	66
Common Stock	101	-	223	237	-	243	303	349
Retained Earnings	-93	-	-130	-161	-	-217	-245	-288
Accumulated Other Comprehensive Income / (Loss)	12	-	4.57	4.75	-	5.57	2.74	5.03

This table presents Profound Medical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	61	50	42	73
Total Current Assets	60	49	42	70
Cash & Equivalents	46	35	25	50
Accounts Receivable	5.97	4.90	8.17	9.42
Inventories, net	6.80	8.35	8.34	9.00
Prepaid Expenses	0.72	0.37	0.20	0.81
Plant, Property, & Equipment, net	0.31	0.28	0.34	0.68
Total Noncurrent Assets	0.64	0.58	0.44	3.24
Noncurrent Note & Lease Receivables	-	-	-	0.15
Intangible Assets	0.21	0.18	0.12	0.13
Noncurrent Deferred & Refundable Income Taxes	0.09	0.10	0.08	0.07
Other Noncurrent Operating Assets	0.34	0.30	0.24	2.90
Total Liabilities & Shareholders' Equity	61	50	42	73
Total Liabilities	10	10	10	14
Total Current Liabilities	5.30	5.72	9.94	11
Short-Term Debt	0.00	0.00	4.48	4.50
Accounts Payable	1.05	0.95	0.72	2.14
Accrued Expenses	3.35	3.80	3.97	3.39
Current Deferred Revenue	0.64	0.69	0.43	0.46
Current Deferred & Payable Income Tax Liabilities	-	-	0.06	0.04
Other Current Liabilities	0.26	0.28	0.28	0.07
Total Noncurrent Liabilities	4.78	4.69	0.22	3.43
Long-Term Debt	4.49	4.46	0.00	0.00
Noncurrent Deferred Revenue	0.09	0.07	0.15	0.44
Other Noncurrent Operating Liabilities	0.21	0.15	0.08	2.98
Total Equity & Noncontrolling Interests	51	39	32	59
Total Preferred & Common Equity	51	39	32	59
Total Common Equity	51	39	32	59
Common Stock	304	305	307	350
Retained Earnings	-256	-272	-280	-295
Accumulated Other Comprehensive Income / (Loss)	2.85	5.56	4.75	4.02

This table displays calculated financial ratios and metrics derived from Profound Medical's official financial filings.

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	11,852,749.00	20,208,948.00	20,776,217.00	20,879,497.00	21,370,565.00	-	30,193,592.00
DEI Adjusted Shares Outstanding	0.00	11,852,749.00	20,208,948.00	20,776,217.00	20,879,497.00	21,370,565.00	-	30,193,592.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	-1.28	-1.07	-1.48	-1.37	-1.33	-	-1.41
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	118.89%	74.99%	-5.90%	-2.79%	7.75%	48.35%	50.73%
EBITDA Growth	0.00%	9.85%	-47.74%	-43.30%	6.75%	-5.67%	-0.07%	-51.24%
EBIT Growth	0.00%	-0.20%	-43.13%	-41.79%	7.23%	-2.97%	-0.10%	-48.31%
NOPAT Growth	0.00%	-0.74%	-26.56%	-60.58%	-6.06%	10.82%	-15.40%	-24.78%
Net Income Growth	0.00%	-0.05%	-42.04%	-41.98%	6.61%	1.21%	1.79%	-53.04%
EPS Growth	0.00%	-33.82%	-8.76%	20.00%	-8.00%	-2.90%	-16.42%	25.89%
Operating Cash Flow Growth	0.00%	0.00%	-36.70%	-8.68%	-15.38%	12.37%	-3.73%	-62.91%
Free Cash Flow Firm Growth	0.00%	0.00%	-81.27%	-6.63%	32.35%	-76.48%	15.19%	-41.12%
Invested Capital Growth	0.00%	4.47%	68.90%	-1.69%	-53.71%	68.87%	-16.05%	10.22%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	12.60%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-7.32%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-6.87%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.31%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-8.20%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	6.02%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1.83%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-4.98%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	31.66%	57.26%	47.56%	42.95%	45.22%	59.90%	65.89%	70.77%
EBITDA Margin	-789.01%	-324.96%	-274.36%	-417.79%	-400.81%	-393.07%	-265.15%	-266.05%
Operating Margin	-775.85%	-357.07%	-258.26%	-440.72%	-480.86%	-397.99%	-309.57%	-256.27%
EBIT Margin	-789.01%	-361.16%	-295.41%	-445.13%	-424.82%	-405.97%	-273.91%	-269.52%
Profit (Net Income) Margin	-797.88%	-364.69%	-296.03%	-446.66%	-429.11%	-393.43%	-260.45%	-264.44%
Tax Burden Percent	101.12%	100.98%	100.21%	100.34%	101.01%	99.55%	99.99%	100.60%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	97.35%	95.09%	97.53%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-115.91%	-114.21%	-105.22%	-135.65%	-198.38%	-207.95%	-207.69%	-270.13%
ROIC Less NNEP Spread (ROIC-NNEP)	-70.00%	652.67%	-81.91%	-122.70%	-177.05%	-69.41%	-194.22%	-244.16%
Return on Net Nonoperating Assets (RNNOA)	37.95%	-41.77%	60.80%	101.15%	127.26%	26.53%	146.99%	203.01%
Return on Equity (ROE)	-77.95%	-155.98%	-44.42%	-34.50%	-71.12%	-181.42%	-60.70%	-67.12%
Cash Return on Invested Capital (CROIC)	0.00%	-118.58%	-156.46%	-133.94%	-124.95%	-259.18%	-190.25%	-279.84%
Operating Return on Assets (OROA)	-44.09%	-46.98%	-32.05%	-31.97%	-37.54%	-53.93%	-51.24%	-58.75%
Return on Assets (ROA)	-44.59%	-47.43%	-32.11%	-32.08%	-37.92%	-52.27%	-48.72%	-57.64%
Return on Common Equity (ROCE)	-77.95%	-155.98%	-44.42%	-34.50%	-71.12%	-181.42%	-60.70%	-67.12%
Return on Equity Simple (ROE_SIMPLE)	-77.95%	0.00%	-22.21%	-38.08%	0.00%	-90.71%	-46.04%	0.00%
Net Operating Profit after Tax (NOPAT)	-10	-10	-13	-21	-22	-20	-23	-29
NOPAT Margin	-543.09%	-249.95%	-180.78%	-308.51%	-336.60%	-278.59%	-216.70%	-179.39%
Net Nonoperating Expense Percent (NNEP)	-45.91%	-766.89%	-23.30%	-12.94%	-21.33%	-138.54%	-13.47%	-25.96%
Return On Investment Capital (ROIC_SIMPLE)	-36.62%	-	-	-	-	-52.33%	-35.56%	-40.71%
Cost of Revenue to Revenue	68.34%	42.74%	52.44%	57.05%	54.78%	40.10%	34.11%	29.23%
SG&A Expenses to Revenue	413.03%	189.20%	170.11%	261.40%	268.42%	257.52%	216.61%	199.10%
R&D to Revenue	394.48%	225.13%	135.71%	222.28%	219.88%	200.36%	158.85%	127.94%
Operating Expenses to Revenue	807.50%	414.33%	305.82%	483.68%	526.07%	457.88%	375.46%	327.04%
Earnings before Interest and Taxes (EBIT)	-15	-15	-22	-31	-28	-29	-29	-43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-15	-14	-20	-29	-27	-28	-28	-43
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	2.50	2.82	0.00	5.68	2.66	3.58
Price to Tangible Book Value (P/TBV)	0.00	0.00	2.63	2.97	0.00	5.77	2.67	3.58
Price to Revenue (P/Rev)	0.00	0.00	33.36	33.02	33.87	24.62	15.03	14.76
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	10.14	10.31	32.54	13.05	10.84	16.27
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	21.88	23.25	34.94	21.97	10.32	11.33
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	0.45	0.00	0.00	0.00	0.00	0.23	0.08	0.07
Long-Term Debt to Equity	0.40	0.00	0.00	0.00	0.00	0.16	0.05	0.07
Financial Leverage	-0.54	-0.06	-0.74	-0.82	-0.72	-0.38	-0.76	-0.83
Leverage Ratio	1.75	3.29	1.38	1.08	1.88	3.47	1.25	1.16
Compound Leverage Factor	1.75	3.29	1.38	1.08	1.88	3.38	1.18	1.14
Debt to Total Capital	30.99%	100.00%	0.00%	0.00%	100.00%	18.53%	7.16%	6.34%
Short-Term Debt to Total Capital	3.47%	0.00%	0.00%	0.00%	0.00%	5.49%	2.67%	0.00%
Long-Term Debt to Total Capital	27.52%	100.00%	0.00%	0.00%	100.00%	13.05%	4.49%	6.34%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	69.01%	0.00%	100.00%	100.00%	0.00%	81.47%	92.84%	93.66%
Debt to EBITDA	-0.58	-0.69	0.00	0.00	-0.27	-0.25	-0.16	-0.11
Net Debt to EBITDA	0.91	-0.69	0.00	0.00	-0.27	0.68	1.77	1.29
Long-Term Debt to EBITDA	-0.52	-0.69	0.00	0.00	-0.27	-0.18	-0.10	-0.11
Debt to NOPAT	-0.85	-0.89	0.00	0.00	-0.32	-0.35	-0.20	-0.16
Net Debt to NOPAT	1.33	-0.89	0.00	0.00	-0.32	0.95	2.17	1.91
Long-Term Debt to NOPAT	-0.75	-0.89	0.00	0.00	-0.32	-0.25	-0.13	-0.16
Altman Z-Score	0.00	0.00	18.88	19.45	9.83	0.37	4.77	7.16
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	4.81	2.57	20.32	18.56	6.65	6.58	10.52	12.52
Quick Ratio	4.24	1.03	18.99	16.50	2.72	5.26	9.44	11.02
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-11	-20	-21	-14	-25	-21	-30
Operating Cash Flow to CapEx	0.00%	-7,962.96%	-5,878.29%	-3,770.66%	0.00%	0.00%	0.00%	-21,708.52%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	0.06	0.13	0.11	0.07	0.09	0.13	0.19	0.22
Accounts Receivable Turnover	0.97	1.64	1.38	1.55	1.72	1.06	1.49	2.26
Inventory Turnover	0.49	0.56	0.85	0.62	0.48	0.39	0.57	0.67
Fixed Asset Turnover	2.15	0.00	0.00	8.35	0.00	0.00	16.01	28.67
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	1.99	3.34	3.27
Days Sales Outstanding (DSO)	376.89	222.73	263.76	234.81	211.87	345.58	244.92	161.49
Days Inventory Outstanding (DIO)	745.55	647.55	428.80	593.16	765.60	943.79	640.73	544.55
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	183.20	109.31	111.71
Cash Conversion Cycle (CCC)	1,122.43	870.27	692.56	827.97	977.47	1,106.18	776.34	594.33
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	8.94	9.33	16	15	7.17	12	10	11
Invested Capital Turnover	0.21	0.46	0.58	0.44	0.59	0.75	0.96	1.51
Increase / (Decrease) in Invested Capital	0.00	0.40	6.43	-0.27	-8.32	4.94	-1.94	1.04
Enterprise Value (EV)	0.00	0.00	160	160	233	158	110	182
Market Capitalization	0.00	0.00	244	227	226	177	160	238
Book Value per Share	$0.00	$0.00	$8.21	$3.99	$0.00	$1.50	$2.83	$2.20
Tangible Book Value per Share	$0.00	($0.42)	$7.83	$3.79	($0.03)	$1.47	$2.82	$2.20
Total Capital	28	9.33	97	81	7.17	38	65	71
Total Debt	8.76	9.33	0.00	0.00	7.17	7.10	4.66	4.50
Total Long-Term Debt	7.78	9.33	0.00	0.00	7.17	5.00	2.92	4.50
Net Debt	-14	9.33	-84	-67	7.17	-19	-50	-55
Capital Expenditures (CapEx)	0.00	0.19	0.35	0.59	0.00	0.00	0.00	0.18
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.51	4.78	9.02	5.82	13	11	9.33	10
Debt-free Net Working Capital (DFNWC)	23	4.78	93	73	13	38	64	70
Net Working Capital (NWC)	22	4.78	93	73	13	36	63	70
Net Nonoperating Expense (NNE)	4.86	4.79	8.42	9.50	6.18	8.27	4.67	14
Net Nonoperating Obligations (NNO)	-11	9.33	-82	-65	7.17	-19	-50	-55
Total Depreciation and Amortization (D&A)	0.00	1.51	1.54	1.88	1.60	0.93	0.94	0.56
Debt-free, Cash-free Net Working Capital to Revenue	26.64%	114.57%	123.49%	84.65%	197.22%	158.62%	87.31%	63.93%
Debt-free Net Working Capital to Revenue	1,206.31%	114.57%	1,272.36%	1,061.69%	197.22%	522.74%	601.47%	434.92%
Net Working Capital to Revenue	1,154.81%	114.57%	1,272.36%	1,061.69%	197.22%	493.51%	585.21%	434.92%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$1.82	$1.25	$1.50	$1.38	$1.35	$1.12	$1.41
Adjusted Weighted Average Basic Shares Outstanding	0.00	11.85M	20.21M	20.78M	20.88M	21.37M	24.77M	30.23M
Adjusted Diluted Earnings per Share	$0.00	$1.82	$1.25	$1.50	$1.38	$1.35	$1.12	$1.41
Adjusted Weighted Average Diluted Shares Outstanding	0.00	11.85M	20.21M	20.78M	20.88M	21.37M	24.77M	30.23M
Adjusted Basic & Diluted Earnings per Share	$0.00	$1.82	$1.25	$1.50	$1.38	$1.35	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	11.85M	20.21M	20.78M	20.88M	21.37M	30.04M	36.29M
Normalized Net Operating Profit after Tax (NOPAT)	-10	-10	-13	-21	-21	-20	-23	-29
Normalized NOPAT Margin	-543.09%	-249.95%	-180.78%	-308.51%	-310.15%	-278.59%	-216.70%	-179.39%
Pre Tax Income Margin	-789.01%	-361.16%	-295.41%	-445.13%	-424.82%	-395.21%	-260.47%	-262.88%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Profound Medical's official financial filings.

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	21,370,565.00	21,370,565.00	21,370,565.00	21,370,565.00	30,039,809.00	30,053,142.00	30,053,142.00	30,193,592.00	36,293,640.00
DEI Adjusted Shares Outstanding	21,370,565.00	21,370,565.00	21,370,565.00	21,370,565.00	30,039,809.00	30,053,142.00	30,053,142.00	30,193,592.00	36,293,640.00
DEI Earnings Per Adjusted Shares Outstanding	-0.31	-0.32	-0.44	-0.23	-0.36	-0.52	-0.27	-0.27	-0.19
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	82.14%	-0.99%	86.76%	43.13%	103.62%
EBITDA Growth	0.00%	0.00%	0.00%	0.00%	-62.28%	-123.38%	14.82%	-55.31%	33.38%
EBIT Growth	0.00%	0.00%	0.00%	0.00%	-58.81%	-118.16%	15.20%	-50.59%	33.46%
NOPAT Growth	0.00%	0.00%	0.00%	0.00%	-41.75%	-76.05%	0.94%	11.70%	28.17%
Net Income Growth	0.00%	0.00%	0.00%	0.00%	-62.86%	-126.84%	14.82%	-65.23%	34.23%
EPS Growth	0.00%	0.00%	0.00%	0.00%	33.33%	85.71%	-31.58%	42.11%	-47.22%
Operating Cash Flow Growth	0.00%	0.00%	0.00%	0.00%	-82.89%	-121.00%	-40.84%	-11.69%	-3.62%
Free Cash Flow Firm Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	37.55%
Invested Capital Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	10.22%	54.16%
Revenue Q/Q Growth	0.00%	55.18%	26.82%	47.46%	-37.24%	-15.64%	139.21%	13.01%	-10.71%
EBITDA Q/Q Growth	0.00%	-4.90%	-29.71%	42.58%	-107.71%	-44.40%	50.54%	-4.70%	10.90%
EBIT Q/Q Growth	0.00%	-4.50%	-28.49%	41.36%	-101.70%	-43.55%	50.06%	-4.14%	10.87%
NOPAT Q/Q Growth	0.00%	0.44%	-14.74%	7.26%	-33.80%	-23.64%	35.44%	17.32%	-8.85%
Net Income Q/Q Growth	0.00%	-5.07%	-35.35%	47.18%	-116.78%	-46.35%	49.17%	-2.47%	13.71%
EPS Q/Q Growth	0.00%	3.70%	35.71%	-50.00%	89.47%	44.44%	-50.00%	3.85%	-29.63%
Operating Cash Flow Q/Q Growth	0.00%	-37.32%	-9.76%	13.87%	-40.89%	-65.93%	30.05%	31.70%	-30.72%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-9.19%	0.85%	65.64%	-67.87%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-13.06%	-3.58%	38.37%	-4.98%	21.61%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	60.18%	63.64%	63.14%	70.93%	70.70%	73.18%	74.32%	66.77%	71.80%
EBITDA Margin	-469.56%	-317.42%	-324.65%	-126.41%	-418.35%	-716.10%	-148.06%	-137.18%	-136.87%
Operating Margin	-547.39%	-351.19%	-317.73%	-199.83%	-426.02%	-624.42%	-168.52%	-123.29%	-150.29%
EBIT Margin	-486.94%	-327.90%	-332.20%	-132.11%	-424.57%	-722.48%	-150.84%	-139.00%	-138.75%
Profit (Net Income) Margin	-457.61%	-309.85%	-330.69%	-118.46%	-409.16%	-709.86%	-150.82%	-136.76%	-132.15%
Tax Burden Percent	100.61%	100.28%	101.93%	95.41%	100.38%	100.41%	101.54%	100.32%	100.36%
Interest Burden Percent	93.41%	94.24%	97.66%	93.98%	96.00%	97.85%	98.47%	98.07%	94.91%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	-146.88%	-800.05%	-1,213.99%	-285.92%	-129.96%	-176.13%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	-148.66%	-786.19%	-1,174.74%	-268.84%	-124.24%	-172.85%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	123.64%	649.30%	919.62%	170.17%	103.30%	137.61%
Return on Equity (ROE)	0.00%	0.00%	0.00%	-23.24%	-150.75%	-294.37%	-115.75%	-26.66%	-38.53%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	-208.43%	0.00%	0.00%	0.00%	-279.84%	-280.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	-24.71%	-82.75%	-172.23%	-50.98%	-30.30%	-38.87%
Return on Assets (ROA)	0.00%	0.00%	0.00%	-22.16%	-79.74%	-169.22%	-50.97%	-29.81%	-37.02%
Return on Common Equity (ROCE)	0.00%	0.00%	0.00%	-23.24%	-150.75%	-294.37%	-115.75%	-26.66%	-38.53%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-5.51	-5.49	-6.30	-5.84	-7.82	-9.66	-6.24	-5.16	-5.61
NOPAT Margin	-383.18%	-245.83%	-222.41%	-139.88%	-298.21%	-437.10%	-117.96%	-86.30%	-105.20%
Net Nonoperating Expense Percent (NNEP)	0.00%	0.00%	0.00%	1.78%	-13.86%	-39.25%	-17.08%	-5.72%	-3.28%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-8.98%	-14.14%	-22.10%	-17.04%	-7.27%	-8.78%
Cost of Revenue to Revenue	39.82%	36.36%	36.86%	29.07%	29.30%	26.82%	25.68%	33.23%	28.20%
SG&A Expenses to Revenue	333.43%	226.51%	233.76%	159.43%	313.28%	421.80%	140.40%	118.59%	123.50%
R&D to Revenue	274.15%	188.31%	147.10%	111.33%	183.44%	275.80%	102.44%	71.47%	98.59%
Operating Expenses to Revenue	607.57%	414.82%	380.86%	270.76%	496.72%	697.60%	242.84%	190.06%	222.09%
Earnings before Interest and Taxes (EBIT)	-7.01	-7.32	-9.41	-5.52	-11	-16	-7.98	-8.31	-7.41
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-6.76	-7.09	-9.19	-5.28	-11	-16	-7.83	-8.20	-7.31
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	2.66	3.44	4.52	4.57	3.58	3.96
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	2.67	3.46	4.54	4.59	3.58	3.97
Price to Revenue (P/Rev)	0.00	0.00	0.00	15.03	14.74	14.98	10.28	14.76	12.50
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	10.84	15.03	17.19	10.73	16.27	13.89
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	10.32	11.20	12.38	8.86	11.33	10.07
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.08	0.09	0.11	0.14	0.07	0.08
Long-Term Debt to Equity	0.00	0.00	0.00	0.05	0.09	0.11	0.00	0.07	0.00
Financial Leverage	0.00	0.00	0.00	-0.83	-0.83	-0.78	-0.63	-0.83	-0.80
Leverage Ratio	0.00	0.00	0.00	1.25	1.20	1.27	1.32	1.16	1.22
Compound Leverage Factor	0.00	0.00	0.00	1.17	1.15	1.24	1.30	1.14	1.16
Debt to Total Capital	0.00%	0.00%	0.00%	7.16%	8.12%	10.21%	12.23%	6.34%	7.04%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	2.67%	0.00%	0.00%	12.23%	0.00%	7.04%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	4.49%	8.12%	10.21%	0.00%	6.34%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	0.00%	0.00%	92.84%	91.88%	89.79%	87.77%	93.66%	92.96%
Debt to EBITDA	0.00	0.00	0.00	-0.16	-0.14	-0.11	-0.11	-0.11	-0.12
Net Debt to EBITDA	0.00	0.00	0.00	1.77	1.29	0.74	0.51	1.29	1.17
Long-Term Debt to EBITDA	0.00	0.00	0.00	-0.10	-0.14	-0.11	0.00	-0.11	0.00
Debt to NOPAT	0.00	0.00	0.00	-0.20	-0.18	-0.15	-0.15	-0.16	-0.17
Net Debt to NOPAT	0.00	0.00	0.00	2.17	1.65	1.04	0.69	1.91	1.72
Long-Term Debt to NOPAT	0.00	0.00	0.00	-0.13	-0.18	-0.15	0.00	-0.16	0.00
Altman Z-Score	0.00	0.00	0.00	5.89	5.20	2.78	0.04	8.65	5.32
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	0.00	0.00	10.52	11.31	8.53	4.18	12.52	6.56
Quick Ratio	0.00	0.00	0.00	9.44	9.90	7.00	3.32	11.02	5.63
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	0.00	0.00	0.00	-17	-18	-18	-6.20	-10
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.19	0.19	0.24	0.34	0.22	0.28
Accounts Receivable Turnover	0.00	0.00	0.00	1.49	1.99	2.42	1.75	2.26	2.45
Inventory Turnover	0.00	0.00	0.00	0.57	0.56	0.43	0.47	0.67	0.69
Fixed Asset Turnover	0.00	0.00	0.00	16.01	38.39	42.59	42.30	28.67	37.97
Accounts Payable Turnover	0.00	0.00	0.00	3.34	3.66	3.81	5.49	3.27	3.41
Days Sales Outstanding (DSO)	0.00	0.00	0.00	244.92	183.58	150.99	208.48	161.49	149.28
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	640.73	646.22	842.46	773.71	544.55	529.73
Days Payable Outstanding (DPO)	0.00	0.00	0.00	109.31	99.67	95.71	66.54	111.71	106.98
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	776.34	730.13	897.74	915.65	594.33	572.02
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	0.00	0.00	10	8.84	8.53	12	11	14
Invested Capital Turnover	0.00	0.00	0.00	1.05	2.68	2.78	2.42	1.51	1.67
Increase / (Decrease) in Invested Capital	0.00	0.00	0.00	0.00	8.84	8.53	12	1.04	4.79
Enterprise Value (EV)	0.00	0.00	0.00	110	133	147	127	182	189
Market Capitalization	182	179	170	160	175	177	147	238	235
Book Value per Share	$0.00	$0.00	$0.00	$2.83	$1.69	$1.31	$1.07	$2.20	$1.64
Tangible Book Value per Share	$0.00	$0.00	$0.00	$2.82	$1.68	$1.30	$1.07	$2.20	$1.63
Total Capital	0.00	0.00	0.00	65	55	44	37	71	64
Total Debt	0.00	0.00	0.00	4.66	4.49	4.46	4.48	4.50	4.50
Total Long-Term Debt	0.00	0.00	0.00	2.92	4.49	4.46	0.00	4.50	0.00
Net Debt	0.00	0.00	0.00	-50	-42	-31	-20	-55	-46
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	0.00	0.00	9.33	8.18	7.89	11	10	13
Debt-free Net Working Capital (DFNWC)	0.00	0.00	0.00	64	55	43	36	70	63
Net Working Capital (NWC)	0.00	0.00	0.00	63	55	43	32	70	59
Net Nonoperating Expense (NNE)	1.07	1.43	3.07	-0.89	2.91	6.03	1.74	3.02	1.44
Net Nonoperating Obligations (NNO)	0.00	0.00	0.00	-50	-42	-31	-20	-55	-46
Total Depreciation and Amortization (D&A)	0.25	0.23	0.21	0.24	0.16	0.14	0.15	0.11	0.10
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	87.31%	68.99%	66.66%	78.62%	63.93%	69.79%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	601.47%	460.44%	363.91%	252.26%	434.92%	337.12%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	585.21%	460.44%	363.91%	220.93%	434.92%	313.19%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.19	$0.36	$0.52	$0.26	$0.27	$0.19
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	0.00	24.77M	30.04M	30.05M	30.10M	30.23M	36.30M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.19	$0.36	$0.52	$0.26	$0.27	$0.19
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	0.00	24.77M	30.04M	30.05M	30.10M	30.23M	36.30M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	0.00	30.04M	30.05M	30.05M	30.19M	36.29M	36.34M
Normalized Net Operating Profit after Tax (NOPAT)	-5.51	-5.49	-6.30	-5.84	-7.82	-9.66	-6.24	-5.16	-5.61
Normalized NOPAT Margin	-383.18%	-245.83%	-222.41%	-139.88%	-298.21%	-437.10%	-117.96%	-86.30%	-105.20%
Pre Tax Income Margin	-454.83%	-309.00%	-324.44%	-124.16%	-407.59%	-706.97%	-148.53%	-136.32%	-131.68%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Profound Medical (NASDAQ: PROF) continues to look like a company in growth mode, but one that is still spending heavily and burning cash. Revenue has improved meaningfully over the last year, yet losses remain large and operating cash flow is still negative. The biggest takeaway from the latest quarter is that the company ended Q1 2026 with a much larger cash balance than it had a year ago, which gives it more runway, but profitability is still a distant goal.

Revenue rose to $5.3 million in Q1 2026 from $2.6 million in Q1 2025, showing continued top-line growth year over year.
Gross profit improved to $3.8 million, with gross margin staying strong at roughly 72% in Q1 2026.
Cash and equivalents jumped to $50.3 million at March 31, 2026, up from $24.8 million at the end of Q3 2025.
The balance sheet shows no long-term debt, which reduces financial risk and gives the company flexibility.
Current assets of $69.5 million versus current liabilities of $10.6 million point to a solid near-term liquidity position.
The company still has a large accumulated deficit, with retained earnings of -$294.8 million, reflecting years of losses.
Shares outstanding remain elevated, with basic weighted average shares of about 36.3 million in Q1 2026, which can limit per-share upside.
Operating expenses were still far above gross profit, leading to an operating loss of $8.0 million in Q1 2026.
The company reported a net loss of $7.1 million in Q1 2026, even after interest and other income.
Operating cash flow was negative $8.6 million in Q1 2026, showing the business is still consuming cash from core operations.

Looking at the broader trend, revenue has improved from $1.4 million in Q1 2024 to $5.3 million in Q1 2026, which is a positive sign for commercial adoption. But expenses have also remained elevated, especially SG&A and R&D, so the company has not yet translated growth into operating leverage. Even in its stronger revenue periods, losses have stayed in the high-single-digit millions per quarter.

One important positive is the company’s liquidity profile. Profound Medical appears well-capitalized for the near term, and its debt-free structure helps reduce balance-sheet stress. That said, investors should keep an eye on the pace of cash burn. The latest quarter shows that while the company is growing, it is still relying on its cash balance to fund operations.

Bottom line: Profound Medical’s latest numbers show improving revenue and a strong cash position, but the company is still far from profitability and continues to burn cash at a meaningful rate. For retail investors, this makes PROF a growth story with significant execution risk.

07/25/26 10:47 AM ETAI Generated. May Contain Errors.

Profound Medical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Profound Medical's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Profound Medical's net income appears to be on an upward trend, with a most recent value of -$42.57 million in 2025, rising from -$15.21 million in 2018. The previous period was -$27.82 million in 2024. Find out what analysts predict for Profound Medical in the coming months.

Profound Medical's total operating income in 2025 was -$41.25 million, based on the following breakdown:

Total Gross Profit: $11.39 million
Total Operating Expenses: $52.65 million

Over the last 7 years, Profound Medical's total revenue changed from $1.91 million in 2018 to $16.10 million in 2025, a change of 744.2%.

Profound Medical's total liabilities were at $11.04 million at the end of 2025, a 12.5% increase from 2024, and a 24.4% decrease since 2018.

In the past 7 years, Profound Medical's cash and equivalents has ranged from $0.00 in 2019 to $83.91 million in 2020, and is currently $59.72 million as of their latest financial filing in 2025.

Over the last 7 years, Profound Medical's book value per share changed from 0.00 in 2018 to 2.20 in 2025, a change of 220.0%.

Related Companies

Financial statements for NASDAQ:PROF last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Profound Medical (PROF) Financials

Financials Breakdown Chart

Key Financial Trends

Profound Medical Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Profound Medical (PROF) Financials

Annual Income Statements for Profound Medical

Quarterly Income Statements for Profound Medical

Annual Cash Flow Statements for Profound Medical

Quarterly Cash Flow Statements for Profound Medical

Annual Balance Sheets for Profound Medical

Quarterly Balance Sheets for Profound Medical

Annual Metrics And Ratios for Profound Medical

Quarterly Metrics And Ratios for Profound Medical

Financials Breakdown Chart

Key Financial Trends

Profound Medical Financials - Frequently Asked Questions

When does Profound Medical's fiscal year end?

How has Profound Medical's net income changed over the last 7 years?

What is Profound Medical's operating income?

How has Profound Medical's revenue changed over the last 7 years?

How much debt does Profound Medical have?

How much cash does Profound Medical have?

How has Profound Medical's book value per share changed over the last 7 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools